Upwards Drift of Cerebrospinal Fluid Amyloid-β 42 over Twelve Years in a Consecutive Clinical Cohort

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Upwards Drift of Cerebrospinal Fluid Amyloid-β 42 over Twelve Years in a Consecutive Clinical Cohort. / Simonsen, Anja Hviid; Musaeus, Christian Sandøe; Christensen, Gitte Lund; Hasselbalch, Steen Gregers; Waldemar, Gunhild.

I: Journal of Alzheimer's Disease, Bind 81, Nr. 4, 2021, s. 1369-1373.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Simonsen, AH, Musaeus, CS, Christensen, GL, Hasselbalch, SG & Waldemar, G 2021, 'Upwards Drift of Cerebrospinal Fluid Amyloid-β 42 over Twelve Years in a Consecutive Clinical Cohort', Journal of Alzheimer's Disease, bind 81, nr. 4, s. 1369-1373. https://doi.org/10.3233/JAD-201506

APA

Simonsen, A. H., Musaeus, C. S., Christensen, G. L., Hasselbalch, S. G., & Waldemar, G. (2021). Upwards Drift of Cerebrospinal Fluid Amyloid-β 42 over Twelve Years in a Consecutive Clinical Cohort. Journal of Alzheimer's Disease, 81(4), 1369-1373. https://doi.org/10.3233/JAD-201506

Vancouver

Simonsen AH, Musaeus CS, Christensen GL, Hasselbalch SG, Waldemar G. Upwards Drift of Cerebrospinal Fluid Amyloid-β 42 over Twelve Years in a Consecutive Clinical Cohort. Journal of Alzheimer's Disease. 2021;81(4):1369-1373. https://doi.org/10.3233/JAD-201506

Author

Simonsen, Anja Hviid ; Musaeus, Christian Sandøe ; Christensen, Gitte Lund ; Hasselbalch, Steen Gregers ; Waldemar, Gunhild. / Upwards Drift of Cerebrospinal Fluid Amyloid-β 42 over Twelve Years in a Consecutive Clinical Cohort. I: Journal of Alzheimer's Disease. 2021 ; Bind 81, Nr. 4. s. 1369-1373.

Bibtex

@article{4bbdfd37e85a488f9a057ce674aa27c1,
title = "Upwards Drift of Cerebrospinal Fluid Amyloid-β 42 over Twelve Years in a Consecutive Clinical Cohort",
abstract = "Amyloid-β 1-42 (Aβ1-42) measured in the cerebrospinal fluid (CSF) can be used as a diagnostic biomarker for Alzheimer's disease (AD) but an upward drift when using the INNOTEST ELISA has been suggested. We investigated the upwards drift of Aβ1-42 levels over a period of twelve years in a consecutive memory clinic cohort. We found a significant increase in Aβ1-42 from 2008 to 2019 independent of changes in tau. New methods for the quantification of CSF Aβ1-42 levels are being implemented but awareness of this upwards drift is crucial during the diagnostic work-up and when selecting historical samples for research.",
keywords = "Alzheimer's disease, amyloid-β 42, biomarker, cerebrospinal fluid",
author = "Simonsen, {Anja Hviid} and Musaeus, {Christian Sand{\o}e} and Christensen, {Gitte Lund} and Hasselbalch, {Steen Gregers} and Gunhild Waldemar",
note = "Funding Information: This work is supported by the Simon Spies Foundation, Absalon Foundation, The Danish Order of Freemasons - Grand Lodge of Denmark, and Ellen M{\o}rchs Fond. Publisher Copyright: {\textcopyright} 2021-IOS Press. All rights reserved.",
year = "2021",
doi = "10.3233/JAD-201506",
language = "English",
volume = "81",
pages = "1369--1373",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "I O S Press",
number = "4",

}

RIS

TY - JOUR

T1 - Upwards Drift of Cerebrospinal Fluid Amyloid-β 42 over Twelve Years in a Consecutive Clinical Cohort

AU - Simonsen, Anja Hviid

AU - Musaeus, Christian Sandøe

AU - Christensen, Gitte Lund

AU - Hasselbalch, Steen Gregers

AU - Waldemar, Gunhild

N1 - Funding Information: This work is supported by the Simon Spies Foundation, Absalon Foundation, The Danish Order of Freemasons - Grand Lodge of Denmark, and Ellen Mørchs Fond. Publisher Copyright: © 2021-IOS Press. All rights reserved.

PY - 2021

Y1 - 2021

N2 - Amyloid-β 1-42 (Aβ1-42) measured in the cerebrospinal fluid (CSF) can be used as a diagnostic biomarker for Alzheimer's disease (AD) but an upward drift when using the INNOTEST ELISA has been suggested. We investigated the upwards drift of Aβ1-42 levels over a period of twelve years in a consecutive memory clinic cohort. We found a significant increase in Aβ1-42 from 2008 to 2019 independent of changes in tau. New methods for the quantification of CSF Aβ1-42 levels are being implemented but awareness of this upwards drift is crucial during the diagnostic work-up and when selecting historical samples for research.

AB - Amyloid-β 1-42 (Aβ1-42) measured in the cerebrospinal fluid (CSF) can be used as a diagnostic biomarker for Alzheimer's disease (AD) but an upward drift when using the INNOTEST ELISA has been suggested. We investigated the upwards drift of Aβ1-42 levels over a period of twelve years in a consecutive memory clinic cohort. We found a significant increase in Aβ1-42 from 2008 to 2019 independent of changes in tau. New methods for the quantification of CSF Aβ1-42 levels are being implemented but awareness of this upwards drift is crucial during the diagnostic work-up and when selecting historical samples for research.

KW - Alzheimer's disease

KW - amyloid-β 42

KW - biomarker

KW - cerebrospinal fluid

U2 - 10.3233/JAD-201506

DO - 10.3233/JAD-201506

M3 - Journal article

C2 - 33935081

AN - SCOPUS:85108234882

VL - 81

SP - 1369

EP - 1373

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 4

ER -

ID: 301627888